Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > BCMA > EP-118

BCMA [Biotinylated] : BAFF Inhibitor Screening ELISA Kit

For research use only.

Order Now

EP118-C01High-bind Plate1 plate
EP118-C02Human BAFF10 μg
EP118-C03Biotinylated Human BCMA10 μg
EP118-C04Anti-BCMA Neutralizing Antibody20 μg
EP118-C05Streptavidin-HRP5 μg
EP118-C06Coating Buffer12 mL
EP118-C0710xWashing Buffer 50 mL
EP118-C08Blocking Buffer50 mL
EP118-C09Substrate Solution12 mL
EP118-C10Stop Solution7 mL
  • Background
    TNFRSF17 is a member of the TNF-receptor family, known as tumor necrosis factor receptor superfamily member 17, also known as B cell maturation antigen (BCMA or BCM) or CD269. It is a protein encoded by TNFRSF17 gene.  The receptor is expressed on the surface of B lymphocytes and plasma cells and is a marker protein of B lymphocyte maturation.The main ligands of BCMA are BAFF and APRIL. BCMA combined with BAFF could activate the classical and non-classical NF-κB and JNK signaling pathways, up-regulate the expression of anti-apoptotic protein and down-regulate the expression of pro-apoptotic protein. When BCMA binds to APRIL, the expression level of immune checkpoint is up-regulated, creating an immunosuppressed bone marrow microenvironment.
  • Application

    This kit is developed for screening for inhibitors of human BCMA binding to human BAFF.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening Assay kit is designed to facilitate the identification and characterization of new BCMA pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human BCMA to immobilized human BAFF in a functional chemiluminescence assay. Briefly, we provide you with a human Biotinylated BCMA protein, a human BAFF protein, an anti-BCMA neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human BAFF.

    b) Add your molecule of interest to the tests.

    c) Add human BCMA-Biotin to bind the coated human BAFF.

    d) Add Streptavidin-HRP followed by luminol .

    Finally, the half maximal inhibitory concentration (IC50) of your compound to BCMA: BAFF binding will be determined by comparing RLU readings among different experimental groups.

Typical Data Please refer to Ds document for the assay protocol.

Serial dilutions of Anti-BCMA Neutralizing antibody (Catalog # EP118-C04) (1:1 serial dilution, from 10 μg/mL to 0.0048828125μg/mL) was added into BAFF: Biotinylated BCMA binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:6 Details
  • Number of Drugs in Clinical Trials:89 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message